Atea’s AT-527, an Oral Antiviral Drug Candidate, Reduces Viral Replication in Hospitalized Patients with COVID-19 in Phase 2 Interim Analysis

David Linetsky
Point-of-Care Marketing

Paul Theisen
Patient Acquisition

Liz Kane
Impactful Strategy

Joey Cohen
Medication Adherence

Bud Bilanich
Success Coach

Pat Purcell
Meeting Engagement

Daniel Sontupe
Market Access

Matt Turner
Patient Affordability

Frank Burrell
Scientific Storytelling

Matthew Durham
Omnidynamic Marketing

Brenda Snow
Authentic Patient Voice

Suma Ramadas, PhD
Medical Affairs

Amy Giles
Increasing Engagement

Stacey Gandler
Brand Nourishment